Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 5/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.55 |
| ▸ | RELA | Q04206 | 5/20 | 0.55 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22084065 | 1.00 | NFKB1 (0.55) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL22426005 | 1.00 | NFKB1 (0.55) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL22242697 | 1.00 | NFKB1 (0.55) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL4714078 | 0.85 | NFKB1 (0.54) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL4714074 | 0.85 | NFKB1 (0.54) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL4714079 | 0.85 | NFKB1 (0.54) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL22084467 | 0.83 | NFKB1 (0.55) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL14586680 | 0.83 | NFKB1 (0.55) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL2630497 | 0.83 | NFKB1 (0.55) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL22084627 | 0.83 | NFKB1 (0.55) | NFKB1NFKB2RELABTKKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528822-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| US-12060365-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-08-13 | — | — | US | disclosed |
| EP-3892278-B1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2024-02-28 | — | — | EP | disclosed |
| EP-3892278-B1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2024-02-28 | — | — | EP | disclosed |
| US-20230074669-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-03-09 | — | — | US | disclosed |
| US-20230074669-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-03-09 | — | — | US | disclosed |
| US-20230030720-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-02 | — | — | US | disclosed |
| US-20230030720-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-02 | — | — | US | disclosed |
| US-11236106-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-02-01 | — | — | US | disclosed |
| US-11236106-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-02-01 | — | — | US | disclosed |
| EP-3892278-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2021-10-13 | — | — | EP | disclosed |
| CN-113164481-A | Cycloalkane-1, 3-diamine derivatives | 第一三共株式会社 | 2021-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236106-B2 | Cycloalkane-1,3-diamine derivative | MLLT1, MEN1, MLLT3 | NFKB1 1866/4885NFKB2 1594/4885RELA 1292/4885 |
| US-12060365-B2 | Cycloalkane-1,3-diamine derivative | MLLT1, MEN1, MLLT3 | NFKB1 1866/4885NFKB2 1594/4885RELA 1292/4885 |
| US-20230030720-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | MLLT1, MEN1, MLLT3 | NFKB1 1866/4885NFKB2 1594/4885RELA 1292/4885 |
| US-12528822-B2 | Cycloalkane-1,3-diamine derivative | MLLT1, MLLT3, PRMT6 | NFKB1 2464/4885NFKB2 2073/4885RELA 1628/4885 |
| US-20230074669-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | MLLT1, MEN1, MLLT3 | NFKB1 1866/4885NFKB2 1594/4885RELA 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.